MGMT and central nervous system cancer: Moreover, the inverse correlation between ESURATAG-GS and MGMT promoter methylation in gliomas (Supplementary Figure S3), a key determinant of therapeutic response (Bobola et al., 2015), suggests that tumors with high ER stress burden may be more resistant to standard alkylating chemotherapy, reinforcing the therapeutic relevance of this pathway.